2nd Interstitial Lung Disease Drug Development Summit
Evvnt Promotion / evvnt
Archivio
07.03.2022 - 09.03.2022Online, USA
Time: 9:00 AM - 5:05 PM
Temi della conferenza With SSc-ILD on the cusp of regulatory approval following closely behind Pirfenidone’s breakthrough therapy designation to treat uILD earlier this year, and investment pouring across multiple ILD phenotypes, the window of therapeutic opportunity to develop clinically defining drugs to treat interstitial lung disease is well and truly open.